Market Place
Sourcing Support
Evaxion To Unveil Business Update And Q3 2025 Financials
31 Oct 2025 //
GLOBENEWSWIRE
Evaxion Extends Cash Runway To 2nd Half Of 2027 With $7.2M Raise
30 Oct 2025 //
GLOBENEWSWIRE
Evaxion`s Business Update and Q2 2025 Financial Results
11 Aug 2025 //
GLOBENEWSWIRE
Evaxion and EIB Agree to Convert Debt into Equity
11 Jul 2025 //
GLOBENEWSWIRE
Evaxion Updates Business and Q1 2025 Financial Results
27 May 2025 //
GLOBENEWSWIRE
Evaxion to announce Q1 2025 results on May 27, 2025
23 May 2025 //
GLOBENEWSWIRE
Nasdaq Confirms Evaxion Compliance, Withdraws Delisting Notice
14 Feb 2025 //
GLOBENEWSWIRE
Evaxion announces pricing of $10.8 million public offering
30 Jan 2025 //
GLOBENEWSWIRE
Evaxion Appeals Nasdaq Delisting, Remains Committed to Listing
13 Nov 2024 //
GLOBENEWSWIRE
Evaxion To Announce Q2 2024 Results And Business Update On August 14
12 Aug 2024 //
GLOBENEWSWIRE
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
03 Jul 2024 //
GLOBENEWSWIRE
Evaxion Announces Business Update and First Quarter 2024 Financial Results
28 May 2024 //
GLOBENEWSWIRE
Evaxion Receives Nasdaq Notification
10 May 2024 //
GLOBENEWSWIRE
Evaxion to Host R&D Day on March 19, 2024, Highlighting Technology Innovations
29 Feb 2024 //
GLOBENEWSWIRE
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
07 Feb 2024 //
GLOBENEWSWIRE
Evaxion Announces Closing of $15 Million Public Offering
06 Feb 2024 //
GLOBENEWSWIRE
Evaxion Announces Completion of ADS Ratio Change
22 Jan 2024 //
GLOBENEWSWIRE
Evaxion Announces Plan to Implement ADS Ratio Change
08 Jan 2024 //
GLOBENEWSWIRE
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
19 Dec 2023 //
GLOBENEWSWIRE
Evaxion Presents Principle for AI Model Predicting Responses to Cancer Immunotherapy
15 Nov 2023 //
GLOBENEWSWIRE
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
05 Oct 2023 //
GLOBENEWSWIRE
Evaxion announces Executive Management Changes to strengthen the AI-strategy
29 Aug 2023 //
GLOBENEWSWIRE
Evaxion Announces Business Update and First Quarter 2023 Financial Results
31 May 2023 //
GLOBENEWSWIRE
Evaxion teases 67% response rate in PhI metastatic melanoma trial
26 May 2023 //
ENDPTS
Evaxion to host R&D Day on May 25, 2023
16 May 2023 //
GLOBENEWSWIRE
Fourth quarter and full year 2022 financial results and business update
27 Apr 2023 //
GLOBENEWSWIRE
Evaxion Announces Fast-Tracking of its New AI Discovery to Patients
28 Mar 2023 //
GLOBENEWSWIRE
Evaxion presents a new source of AI-derived immunotherapeutic targets
23 Mar 2023 //
GLOBENEWSWIRE
Evaxion receives fast-track designation for personalized cancer immunotherapy
19 Jan 2023 //
GLOBENEWSWIRE
Evaxion to present readout on personalized cancer immunotherapies in Q2 2023
15 Dec 2022 //
GLOBENEWSWIRE
Evaxion & ExpreS²ion initiate research collaboration on a novel (CMV) vaccine
06 Dec 2022 //
GLOBENEWSWIRE
Evaxion and ExpreS²ion partner to develop new CMV vaccine
06 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
Evaxion announces promising results from Ph1/2a clinical trial
17 Nov 2022 //
GLOBENEWSWIRE
Evaxion Announces Third Quarter 2022 Financial Results and Business Update
14 Nov 2022 //
GLOBENEWSWIRE
3 more biotechs look to cull, partner assets
14 Nov 2022 //
FIERCEBIOTECH
Evaxion Announces NIH Grant for Research Collaboration With Umass
06 Sep 2022 //
GLOBENEWSWIRE
Evaxion Biotech Announces Q2 Financial Results and Provides Business Update
10 Aug 2022 //
GLOBENEWSWIRE
Evaxion Biotech A/S Names Per Norlén as CEO
03 Aug 2022 //
CONTRACTPHARMA
Evaxion Biotech A/S Announces Executive Management Changes
02 Aug 2022 //
GLOBENEWSWIRE
CEO of Danish immunotherapy startup hits the exit in the latest C-suite shakeup
02 Aug 2022 //
ENDPTS
Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call
29 Jul 2022 //
GLOBENEWSWIRE
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
30 Jun 2022 //
GLOBENEWSWIRE
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into NSCLC
23 Jun 2022 //
GLOBENEWSWIRE
Evaxion Biotech Secures Equity Financing of up to $40M from Lincoln Park Capital
07 Jun 2022 //
GLOBENEWSWIRE
Evaxion Biotech Announces First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Evaxion Biotech Successfully Produces Personalized Cancer Immunotherapies
10 May 2022 //
GLOBENEWSWIRE
Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call
29 Apr 2022 //
GLOBENEWSWIRE
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform for Late-Stage Melanoma
26 Apr 2022 //
BUSINESSWIRE
Evaxion Biotech Hosting Key Opinion Leader Webinar
06 Apr 2022 //
GLOBENEWSWIRE
Evaxion Biotech Announces Q4 and Full Year 2021 Financial Results
22 Mar 2022 //
GLOBENEWSWIRE
Evaxion Biotech Strengthens Management Team with Two Senior Appointments
14 Mar 2022 //
GLOBENEWSWIRE
Evaxion Biotech Completes Recruitment for P 1/2a Trial for EVX-02
07 Mar 2022 //
GLOBENEWSWIRE
Evaxion Biotech Publishes Clinical Data of EVX-01 Heading into Phase 2b
26 Jan 2022 //
GLOBENEWSWIRE
Evaxion Biotech Bags Regulatory Clearance to Initiate Phase 2 Trial of EVX-01
18 Jan 2022 //
GLOBENEWSWIRE
Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering
09 Nov 2021 //
GLOBENEWSWIRE
Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
05 Nov 2021 //
GLOBENEWSWIRE
Evaxion Biotech Announces Filing of Registration Statement in the U.S
26 Oct 2021 //
GLOBENEWSWIRE
EvaxionAnnounces Clinical Collaboration to Evaluate Lead Product KEYTRUDA®
25 Oct 2021 //
GLOBENEWSWIRE
Evaxion Biotech to Present Work on AI-Immunology Core Technology
12 Oct 2021 //
GLOBENEWSWIRE
